
- English
- ePUB (mobile friendly)
- Available on iOS & Android
Statistical Thinking for Non-Statisticians in Drug Regulation
About this book
STATISTICAL THINKING FOR NON-STATISTICIANS IN DRUG REGULATION
Statistical methods in the pharmaceutical industry are accepted as a key element in the design and analysis of clinical studies. Increasingly, the medical and scientific community are aligning with the regulatory authorities and recognizing that correct statistical methodology is essential as the basis for valid conclusions. In order for those correct and robust methods to be successfully employed there needs to be effective communication across disciplines at all stages of the planning, conducting, analyzing and reporting of clinical studies associated with the development and evaluation of new drugs and devices.
Statistical Thinking for Non-Statisticians in Drug Regulation provides a comprehensive in-depth guide to statistical methodology for pharmaceutical industry professionals, including physicians, investigators, medical science liaisons, clinical research scientists, medical writers, regulatory personnel, statistical programmers, senior data managers and those working in pharmacovigilance. The author's years of experience and up-to-date familiarity with pharmaceutical regulations and statistical practice within the wider clinical community make this an essential guide for the those working in and with the industry.
The third edition of Statistical Thinking for Non-Statisticians in Drug Regulation includes:
- A detailed new chapter on Estimands in line with the 2019 Addendum to ICH E9
- Major new sections on topics including Combining Hierarchical Testing and Alpha Adjustment, Biosimilars, Restricted Mean Survival Time, Composite Endpoints and Cumulative Incidence Functions, Adjusting for Cross-Over in Oncology, Inverse Propensity Score Weighting, and Network Meta-Analysis
- Updated coverage of many existing topics to reflect new and revised guidance from regulatory authorities and author experience
Statistical Thinking for Non-Statisticians in Drug Regulation is a valuable guide for pharmaceutical and medical device industry professionals, as well as statisticians joining the pharmaceutical industry and students and teachers of drug development.
Frequently asked questions
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Information
Table of contents
- Cover
- Table of Contents
- Title Page
- Copyright Page
- Preface to the third edition
- Preface to the second edition
- Preface to the first edition
- Abbreviations
- CHAPTER 1: Basic ideas in clinical trial design
- CHAPTER 2: Sampling and inferential statistics
- CHAPTER 3: Confidence intervals and pâvalues
- CHAPTER 4: Tests for simple treatment comparisons
- CHAPTER 5: Adjusting the analysis
- CHAPTER 6: Regression and analysis of covariance
- CHAPTER 7: Intentionâtoâtreat, analysis sets and missing data
- CHAPTER 8: Estimands
- CHAPTER 9: Power, sample size and clinical relevance
- CHAPTER 10: Multiple testing
- CHAPTER 11: Nonâparametric and related methods
- CHAPTER 12: Equivalence and nonâinferiority
- CHAPTER 13: The analysis of survival data
- CHAPTER 14: Interim analysis and data monitoring committees
- CHAPTER 15: Bayesian statistics
- CHAPTER 16: Adaptive designs
- CHAPTER 17: Observational studies
- CHAPTER 18: Metaâanalysis and network metaâanalysis
- CHAPTER 19: Methods for safety analysis, safety monitoring and assessment of benefitârisk
- CHAPTER 20: Diagnosis
- CHAPTER 21: The role of statistics and statisticians
- References
- Index
- End User License Agreement